[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-60;   61-8081-100101-120121-140141-160; 161-180181-200201-220221-240241-260261-280;  281+

NICE TAs 41-60

 

REF

 

TITLE

 

DHFT Formulary link

East Midlands Cancer Network link (cancer drugs only)

TA41 

Pregnancy - routine anti-D prophylaxis for RhD-negative women (TA41) (replaced by TA156) (withdrawn)                 

Withdrawn                         

                          

TA42

Growth hormone deficiency (children) - human growth hormone (TA42) (replaced by TA188)

Withdrawn   

 

TA43

Schizophrenia - atypical antipsychotics (TA43) (replaced by CG82)

Withdrawn 

 

TA44

Hip disease - metal on metal hip resurfacing (TA44)

No drug implications

 

TA45 

Ovarian cancer (advanced) - pegylated liposomal doxorubicin hydrochloride (TA45) (replaced by TA91) (withdrawn)

Withdrawn

 

 

TA46

Obesity (morbid) - surgery (TA46) (replaced by CG43) (withdrawn)

Withdrawn 

 

TA47

Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47) (partially updated by CG94)  

2.9 Antiplatelet drugs

 

TA48

Renal failure - home versus hospital haemodialysis (TA48)

No drug implications

 

TA49

Central venous catheters - ultrasound locating devices (TA49)  

No drug implications

 

TA50

Leukaemia (chronic myeloid) - imatinib (TA50) (replaced by TA70) (withdrawn)  

Withdrawn

 

TA51

Depression and anxiety - computerised cognitive behaviour therapy (CCBT) (TA51) (replaced by TA97) (withdrawn)  

Withdrawn

 

TA52

Myocardial infarction - thrombolysis (TA52)

2.10 Myocardial Infarct and fibrinolysis

 

TA53

Diabetes (types 1 and 2) - long acting insulin analogues (TA53)  

6.1.1 - 6.1.2.3 Insulin, oral antidiabetic drugs, biguanides: 6.1.1.2 Intermediate and long acting insulins

 

TA54

Breast cancer - vinorelbine (TA54) (replaced by CG81)  

Withdrawn

 

TA55

Ovarian cancer - paclitaxel (review) (TA55)

 

EMCN algorithm

DHFT protocol 

TA56

Stress incontinence - tension-free vaginal tape (TA56) (replaced by CG40) (withdrawn)  

Withdrawn

 

TA57

Diabetes (type 1) - insulin pump therapy (TA57) (replaced by TA151) (withdrawn)

Withdrawn

 

TA58

Flu treatment - zanamivir (review), amantadine and oseltamivir (TA58) (replaced by TA168) (withdrawn)

Withdrawn

 

TA59

Electroconvulsive therapy (ECT) (TA59)  

No drug implications 

 

TA60

Diabetes (types 1 and 2) - patient education models (TA60)  

No drug implications 

 

 

 

 

 

 

 

 

 

: